Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Revenue: 2014-2024

Historic Revenue for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to $80.0 million.

  • Voyager Therapeutics' Revenue fell 45.59% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 80.84%. This contributed to the annual value of $80.0 million for FY2024, which is 68.00% down from last year.
  • According to the latest figures from FY2024, Voyager Therapeutics' Revenue is $80.0 million, which was down 68.00% from $250.0 million recorded in FY2023.
  • In the past 5 years, Voyager Therapeutics' Revenue ranged from a high of $250.0 million in FY2023 and a low of $37.4 million during FY2021.
  • For the 3-year period, Voyager Therapeutics' Revenue averaged around $123.6 million, with its median value being $80.0 million (2024).
  • Per our database at Business Quant, Voyager Therapeutics' Revenue crashed by 78.14% in 2021 and then spiked by 511.16% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' Revenue stood at $171.1 million in 2020, then plummeted by 78.14% to $37.4 million in 2021, then rose by 9.33% to $40.9 million in 2022, then skyrocketed by 511.16% to $250.0 million in 2023, then plummeted by 68.00% to $80.0 million in 2024.